Zepbound®

The active molecule is identical. Zepbound is FDA-approved, manufactured by Eli Lilly, and delivered as a pen or single-dose vial. Compounded tirzepatide is mixed by a state-licensed 503A pharmacy, typically uses multi-dose vial-and-syringe dosing, and is usually less expensive cash-pay. Outcomes are comparable when dosing is matched. The FDA shortage that previously authorized broader 503B compounding was resolved in October 2024, but 503A patient-specific compounding remains available.

Different molecules, different magnitudes. Wegovy is semaglutide (GLP-1 only); Zepbound is tirzepatide (dual GIP/GLP-1). In head-to-head data (SURMOUNT-5, 2025), Zepbound 15 mg produced about 20.2% weight loss vs. about 13.7% for Wegovy 2.4 mg at 72 weeks. Wegovy holds the FDA cardiovascular outcomes label; Zepbound holds the OSA label. Your doctor will recommend based on coverage, side-effect profile, and indication.

Coverage varies dramatically by plan. Many commercial insurers cover Zepbound with prior authorization when you meet the BMI criteria, and the 2024 OSA indication has expanded coverage at some plans. Medicare Part D generally does not cover obesity-only indications but may cover OSA-related use. Our team runs a benefits check and submits prior authorization if needed.

LillyDirect is Eli Lilly’s direct-to-patient program. Single-dose vials run roughly $349/month for the 2.5 mg and 5 mg strengths and $499/month for 7.5, 10, 12.5, and 15 mg, well below the ~$1,060/month list price. Lilly added pen pricing to LillyDirect in 2025. We help you enroll if you are paying cash.

Mounjaro is the same molecule approved for type 2 diabetes; Zepbound is approved for weight management and OSA. Insurance typically dictates the choice — diabetes coverage routes patients to Mounjaro, while obesity coverage routes to Zepbound. Your doctor recommends based on your indication and benefits.

Most patients notice appetite changes within 2–3 weeks of starting the 2.5 mg initiation dose. Meaningful scale movement typically begins around weeks 8–12 as you climb to therapeutic strengths. SURMOUNT-1 participants on 15 mg averaged about 21% body-weight loss at 72 weeks; the 5 mg and 10 mg arms averaged about 15% and 19%.

In December 2024 the FDA expanded Zepbound’s label to include moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for OSA. Approval was based on SURMOUNT-OASIS, which showed substantial reductions in apnea-hypopnea index (AHI). Zepbound is not a CPAP replacement, but for many patients meaningful weight loss reduces or eliminates OSA severity.

Yes, but the pathway has changed. The FDA declared the tirzepatide shortage resolved in October 2024, ending the broad 503B compounding allowance. State-licensed 503A pharmacies can still compound tirzepatide for individual patients with a clinical justification — for example, when a patient needs a non-commercial dose, has an excipient sensitivity, or cannot afford branded pricing. Your doctor evaluates clinical fit case by case.